HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase.

Abstract
Tyrosinase has many advantages as a target antigen for the immunotherapy of patients with melanoma because it is expressed in nearly all melanoma specimens with a high degree of cellular homogeneity, and its distribution in normal tissues is limited to melanocytes. To broaden our ability to direct cellular immune responses against this protein, we pursued an investigation to identify new shared human leukocyte antigen (HLA)-A2.1 restricted epitopes from tyrosinase. Peptides were synthesized that fit a permissive HLA-A2.1 binding motif and did not span common sites of polymorphism. The binding affinity of each peptide to HLA-A2.1 relative to a standard peptide with intermediate binding affinity was evaluated in a competitive inhibition assay. Twelve peptides were selected that had binding affinities within 80% of that of the standard peptide, and these were used to stimulate peripheral blood mononuclear cells (PBMC) in vitro from three HLA-A2.1+ patients with metastatic melanoma. Cytotoxic T lymphocytes that specifically recognized peptide-pulsed target cells as well as HLA-A2.1+ tyrosinase+ melanoma cells were raised from one patient with tyrosinase:8-17 (CLLWSFQTSA). To evaluate further the immunogenicity of this peptide, PBMC from 23 HLA-A2.1+ patients were stimulated in vitro with tyrosinase:8-17. Eleven bulk T-cell cultures demonstrated specific peptide recognition, and six of these also recognized HLA-A2.1+ tyrosinase+ melanoma cells. These data suggest that tyrosinase:8-17 may be clinically useful for the treatment of patients with melanoma.
AuthorsJ P Riley, S A Rosenberg, M R Parkhurst
JournalJournal of immunotherapy (Hagerstown, Md. : 1997) (J Immunother) 2001 May-Jun Vol. 24 Issue 3 Pg. 212-20 ISSN: 1524-9557 [Print] United States
PMID11394498 (Publication Type: Journal Article)
Chemical References
  • Antigens, Neoplasm
  • Cancer Vaccines
  • Cytokines
  • Epitopes
  • HLA-A2 Antigen
  • Peptide Fragments
  • Monophenol Monooxygenase
Topics
  • Amino Acid Sequence
  • Animals
  • Antigens, Neoplasm (genetics, immunology)
  • COS Cells
  • Cancer Vaccines (genetics, immunology, therapeutic use)
  • Cytokines (biosynthesis)
  • Epitopes (genetics, immunology, therapeutic use)
  • HLA-A2 Antigen (genetics, immunology)
  • Humans
  • Melanoma (enzymology, genetics, immunology, therapy)
  • Monophenol Monooxygenase (genetics, immunology, therapeutic use)
  • Peptide Fragments (genetics, immunology, therapeutic use)
  • T-Lymphocytes, Cytotoxic (immunology)
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: